Helus Pharma (Cybin Inc.)HELP

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · helus.com

Clinical-stage pharmaceutical company (legal name Cybin Inc., rebranded Helus Pharma in January 2026, when its US listing moved from NYSE American CYBN to Nasdaq HELP) developing proprietary novel serotonergic agonists for depression, anxiety and other mental health conditions. Its lead program HLP003, an FDA Breakthrough Therapy-designated deuterated psilocin analogue, is in Phase 3 for adjunctive treatment of major depressive disorder; also listed on Cboe Canada under HELP.

Key ratios

ROA

-44.4%TTM

2026 -41.4%2025 -33.1%2024 -27.7%

ROE

-86.9%TTM

2026 -74.6%2025 -44.3%2024 -45.9%

Recent news

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York 2026-09-10 · GlobeNewswire Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York 2026-09-09 · GlobeNewswire Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York 2026-09-03 · GlobeNewswire Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights 2026-08-14 · GlobeNewswire Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston 2026-08-10 · GlobeNewswire Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule 2026-07-21 · PR Newswire

Track HELP in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer